IMMUNE PHARMACEUTICALS INC
IMMUNE PHARMACEUTICALS INC (IMNP): 7 pipeline candidates · ~0 mo cash runway · 7 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
0.3 months
D/E 23.60 · 0% dilution
Lead: Phase 3
7 candidates
N/A
N/A
A transparent, data-derived signal for IMMUNE PHARMACEUTICALS INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$76K
Quarterly Burn
$1.5M
Runway
0.3 mo
Revenue
$0
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (7 candidates)
| Drug | Phase |
|---|---|
| amiket | Phase 2 |
| azixa | Phase 2 |
| bertilimumab | Phase 2 |
| ceplene | Phase 3 |
| crolibulin | Phase 2 |
| lidopain | Phase 2 |
| nanocyclo | Preclinical |
Frequently asked questions
How many drug candidates are in IMMUNE PHARMACEUTICALS INC's pipeline?
IMMUNE PHARMACEUTICALS INC (IMNP) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is IMMUNE PHARMACEUTICALS INC's lead drug candidate?
IMMUNE PHARMACEUTICALS INC's most advanced tracked candidate is amiket (Phase 2) for postherpetic neuralgia ("PHN") and diabetic peripheral neuropathy ("DPN").
What is IMMUNE PHARMACEUTICALS INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, IMMUNE PHARMACEUTICALS INC has approximately 0.3 months of cash runway.
Who is the CEO of IMMUNE PHARMACEUTICALS INC?
Anthony Fiorino Anthony is the chief executive officer of IMMUNE PHARMACEUTICALS INC (IMNP).
Get the full picture on IMMUNE PHARMACEUTICALS INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.